| Title | Interstitial I-125 seeds implantation to treat spinal metastatic and primary paraspinal malignancies |
| Authors | Wang, Junjie Yuan, Huishu Ma, Qingjun Liu, Xiaoguang Wang, Hao Jiang, Yuliang Tian, Suqing Yang, Ruijie |
| Affiliation | Peking Univ, Hosp 3, Ctr Canc, Dept Radiat Oncol, Beijing 100191, Peoples R China. Peking Univ, Hosp 3, Dept Radiol, Beijing 100083, Peoples R China. Peking Univ, Hosp 3, Dept Surg, Beijing 100083, Peoples R China. |
| Keywords | I-125 seed implantation Spinal bone metastases Primary paraspinal malignancies CT-guidance CORD COMPRESSION SURGICAL-MANAGEMENT RADIATION-THERAPY BRACHYTHERAPY CANCER TUMORS SURGERY |
| Issue Date | 2010 |
| Publisher | medical oncology |
| Citation | MEDICAL ONCOLOGY.2010,27,(2),319-326. |
| Abstract | Spinal cord metastatic malignances and locally invasive paraspinal carcinomas were severe pain and disabling complications. The treatment modality was unclear. We retrospectively evaluated the safety and efficacy of I-125 seed implantation for spinal metastatic and paraspinal malignancies in our center. A total of 19 patients and 22 procedures were included in this study. Eight patients received a seed implant in an operation, and 11 patients were implanted percutaneousely under CT-guidance. The number of I-125 seeds implanted ranged from 6 to 100, with a median of 26. The specific activity of I-125 seeds ranged from 0.45 to 0.80 mCi per seed, with a median of 0.5 mCi. The minimal peripheral doses of I-125 seed implantation were 90-140 Gy, with median of 120 Gy. Follow-up ranged from 3 to 69 months with a median of 22 months. All patients tolerated seed implantation well. The 1, 2, 3, and 5 year local control rates were 63%, 47%, 31%, and 3%, respectively, with a median of 22 months (3-61 months). The 1, 2, 3, and 5 year survival rates were 74%, 56%, 43%, and 43%, respectively, with a median of 33 months. Ten patients (52.6%) developed distant metastases. Two (10.5%) patients showed recurrence at 13 and 39 months. Seven (36.8%) patients were still alive, 84% (16/19) of patients had either normal or improved ambulation following seed implant. No myelopathies were encountered. Our study suggests a promising local therapy for a selected population of patients with spinal cord metastatic or paraspinal carcinoma. |
| URI | http://hdl.handle.net/20.500.11897/161601 |
| ISSN | 1357-0560 |
| DOI | 10.1007/s12032-009-9212-1 |
| Indexed | SCI(E) PubMed |
| Appears in Collections: | 第三医院 |
